Low IGFBP7 expression identifies a subset of breast cancers with favorable prognosis and sensitivity to IGF-1 receptor targeting with ganitumab: Data from I-SPY2 and SCAN-B

Christopher Godina, Michael N Pollak, Helena Jernström
doi: https://doi.org/10.1101/2023.12.18.23300129

Article Information

doi 
https://doi.org/10.1101/2023.12.18.23300129
History 
  • December 18, 2023.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. Christopher Godina1,*,
  2. Michael N Pollak2 and
  3. Helena Jernström1,*
  1. 1Division of Oncology, Department of Clinical Sciences in Lund, Lund University and Skåne University Hospital, Barngatan 4, SE-221 85 Lund, Sweden
  2. 2Lady Davis Institute for Medical Research, Jewish General Hospital and Department of Oncology, McGill University, Montreal, QC, Canada
  1. ↵*Corresponding authors: Helena Jernström and Christopher Godina
    Division of Oncology, Department of Clinical Sciences in Lund, Lund University and Skåne University Hospital, Barngatan 4, SE-221 85 Lund, Sweden, christopher.godina{at}med.lu.se, helena.jernstrom{at}med.lu.se
Back to top
Posted December 18, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Low IGFBP7 expression identifies a subset of breast cancers with favorable prognosis and sensitivity to IGF-1 receptor targeting with ganitumab: Data from I-SPY2 and SCAN-B
Christopher Godina, Michael N Pollak, Helena Jernström
medRxiv 2023.12.18.23300129; doi: https://doi.org/10.1101/2023.12.18.23300129
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area